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Abstract
In adults, glioblastomas are the most lethal and most frequent malignant brain tumors, and the poor prognosis
despite aggressive treatment indicates the need to establish novel targets for molecular intervention. The secreted
growth factor pleiotrophin (PTN, HB-GAM, HBNF, OSF-1) shows mitogenic, chemotactic, and transforming activity.
Whereas PTN expression is tightly regulated during embryogenesis and is very limited in normal adult tissues, a
marked PTN up-regulation is seen in tumors including glioblastomas. Likewise, the PTN receptor anaplastic lym-
phoma kinase (ALK) has been shown previously to be upregulated and functionally relevant in glioblastoma. In this
study, we explore the antitumorigenic effects of the simultaneous ribozyme-mediated knockdown of both receptor
and ligand. Various glioblastoma cell lines are analyzed for PTN and ALK expression. Beyond the individual effica-
cies of several specific ribozymes against PTN or ALK, respectively, antiproliferative and proapoptotic effects of a
single gene targeting approach are strongly enhanced on double knockdown of both genes in vitro. More impor-
tantly, this results in the abolishment of tumor growth in an in vivo subcutaneous tumor xenograft model. Finally,
the analysis of various downstream signaling pathways by antibody arrays reveals a distinct pattern of changes in
the activation of signal transduction molecules on PTN/ALK double knockdown. Beyond the already known ones, it
identifies additional pathways relevant for PTN/ALK signaling. We conclude that double targeting of PTN and ALK
leads to enhanced antitumorigenic effects over single knockdown approaches, which offers novel therapeutic op-
tions owing to increased efficacy also after prolonged knockdown.
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Introduction
Glioblastomas, which can progress from lower grade gliomas or arise
de novo, are the most frequent and lethal brain tumors in adults.
Because nearly all patients die within 12 months despite aggressive
treatment including surgery, chemotherapy and radiation [1], the
functional analysis of molecules and pathways relevant in glioblastoma
pathogenesis is of major importance to developing novel therapeutic
strategies based on targeted molecular therapies.
The secreted growth factor pleiotrophin (PTN), also called heparin-
binding growth-associated molecule (HB-GAM), heparin affin regulatory
peptide (HARP), heparin-binding growth factor 8, heparin-binding
neurotrophic factor (HBNF), or osteoblast-specific protein-1 (OSF-1),
is a 15.3-kDa developmentally regulated cytokine, which shows very
limited expression in normal adult tissues, but is markedly upregulated
in various primary human tumors and tumor cell lines [2–10]. In par-
ticular, cDNA arrays [11] as well as ELISA and immunohistochemistry
[12], have shown increased PTN expression in glioblastomas com-
pared to normal human brain tissue, and all WHO III and IV grade
gliomas are positive for PTN [13]. Concomitantly, PTN exerts onco-
genic potential and acts as a mitogenic, chemotactic, and angiogenic
factor in various cells including tumor cell lines and tumors [5,9,14–18].
Abbreviations: PTN, pleiotrophin; ALK, anaplastic lymphoma kinase; MK, midkine
Address all correspondence to: Dr. Achim Aigner, Department of Pharmacology and
Toxicology, Philipps-University Marburg, Karl-v.-Frisch-Strasse 1, D – 35033 Marburg,
Germany. E-mail: aigner@staff.uni-marburg.de
1This work was supported by a grant (AI 24/5-1) from the Deutsche Forschungsge-
meinschaft (DFG) to A.A. and by a fellowship from the FAZIT foundation to M.G.
Received 27 August 2008; Revised 3 November 2008; Accepted 5 November 2008
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.81040
www.neoplasia.com
Volume 11 Number 2 February 2009 pp. 145–156 145
In particular, ribozyme- or antisense- or RNA interference (RNAi)–
mediated gene targeting of PTN has been demonstrated to suppress
the proliferative and tumorigenic effects of PTN with concomitant re-
duction of tumor growth, tumor angiogenesis, and metastatic spread
in various tumor entities [5,19,20] including glioblastoma [21,22].
Previously, PTN has been shown to signal through anaplastic lym-
phoma kinase (ALK) [23–25], a transmembrane tyrosine kinase re-
ceptor, which was first identified as a constitutively active, oncogenic
chimeric nucleophosmin–ALK fusion protein resulting from the
(2;5)(p23;q35) chromosomal translocation in anaplastic large cell
lymphomas [26–28] (see [29] for review). By phage display, PTN
was demonstrated to bind to the extracellular domain of ALK, thus
mediating growth stimulatory [24] and antiapoptotic effects [23].
ALK is overexpressed in glioblastoma compared to normal brain, and
ribozyme-mediated targeting of ALK led to reduced tumor growth of
glioblastoma xenografts in athymic nude mice and increased apoptosis
in the tumors [25]. Additionally, it was shown that PTN interacts with
the receptor-type protein tyrosine phosphatase β/ζ (RPTPβ/ζ) [30],
which is also overexpressed in glioblastoma [11], and that ALK can
be activated through the PTN/RPTPβ/ζ pathway, thus introducing a
unique “alternative mechanism of tyrosine kinase receptor activation”
[31]. This indicates that ALK is involved in all PTN-mediated signal
transduction pathways. The ligand PTN [21] as well as the receptors
ALK [25] and RPTPβ/ζ [32] have been demonstrated to be relevant in
glioblastoma growth, and targeting of each of these gene products exerts
antitumorigenic effects.
In this study, we selected ALK as a central player in PTN-mediated
signal transduction pathways, and PTN as target molecules in a
ribozyme-based approach of gene knockdown. We show that the
combination of both ligand + receptor knockdown leads to increased
antitumor effects. Antiproliferative and proapoptotic effects of single
knockdowns were strongly enhanced on double knockdown of both
proteins in vitro, and even the abolishment of tumor growth was
observed in an in vivo subcutaneous (SC) tumor xenograft model.
Finally, the antibody array–based analysis of various downstream sig-
naling pathways reveals a distinct pattern of changes in the activation
of signal transduction molecules on PTN/ALK double targeting and,
beyond the already known ones, identifies additional pathways as
relevant for PTN/ALK signaling.
Materials and Methods
Cell Lines, Ribozyme Constructs, and Stable Transfection
The glioblastoma cell lines G122, U118, U87, and T98G were ob-
tained from the American Type Culture Collection (ATCC, Manassas,
VA), and the cell line G55T2 was established as described previously
[33]. All cell lines were cultivated under standard conditions (37°C,
5% CO2) in Iscove’s modified Dulbecco’s medium (PAA Laboratories,
Cölbe, Germany) supplemented with 10% fetal calf serum (FCS)
unless indicated otherwise.
Ribozyme expression vectors were constructed by annealing syn-
thetic sense and antisense oligonucleotides containing the hammerhead
ribozyme sequence flanked by PTN- or ALK-specific recognition
sequences as well as a Hind III and a NotI site, and cloning them as
described previously [21,25] into the pRc/CMV vector (Invitrogen,
Carlsbad, CA). Ribozyme sequences were as follows:
PTN 66: 5′-cauucauuuuaagcaggauugccugaguaguccauacuggc-3′,
PTN 261: 5′-cuacauucuaaagcaggauugccugaguagucgggacguug-3′,
ALK 1-3: 5′-agcttggagctatctgatgagtccgttaggacgaaaccagtccgc-3′,
ALK 3-2: 5′-agctttccactgcactgatgagtccgttaggacgaaacaagctgc-3′,
ALK 12-1: 5′-agcttgccgtaattctgatgagtccgttaggacgagaacattccgc-3′.
Stable transfections were performed in six-well plates with 100,000
cells per well and 3 μg of the ribozyme expression vector, or the empty
vector as negative control, using jetPEI as described by the manufac-
turer (Polyplus, Illkirch, France). Selection for stable integrants started
48 hours after transfection by the addition of 1000 μg/ml G418 (PAA
Laboratories) for 3 weeks. For double targeting, stable cell lines were
again cotransfected with 3 μg of the second ribozyme expression vec-
tor + 0.3 μg pcDNA Hygro+ vector (Invitrogen), and 400 μg/ml
hygromycin was used for the selection for stable integrants.
RNA Preparation and Quantitative Reverse
Transcription–Polymerase Chain Reaction
Total RNA from tumor cells was isolated using the Tri reagent
(PEQLAB, Erlangen, Germany) according to the manufacturer’s pro-
tocol. Reverse transcription (RT) was performed using the RevertAid
H Minus First Strand cDNA Synthesis Kit from Fermentas (St.
Leon-Rot, Germany) as follows: 1 μg total RNA was diluted in 12 μl
of diethylpyrocarbonate-treated water and 1 μl of random hexames
primer (0.2 μg/μl) was added, the mixture was incubated at 70°C
for 5 minutes and chilled on ice before adding 4 μl of 5× reaction
buffer, 0.5 μl RNAse inhibitor (20 U/μl), and 2 μl of 10 mM
dNTP mix. After incubating at 25°C for 5 minutes, 1 μl of reverse
transcriptase (200 U/μl) was added, and the mixture was incubated
for 10 minutes under the same conditions and for 60 minutes at
42°C, before stopping the reaction by heating at 70°C for 10 minutes
and chilling on ice. Quantitative polymerase chain reaction (PCR) was
performed in a LightCycler from Roche (Penzberg, Germany) using
the QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol with 4 μl of cDNA (di-
luted 1:100), 5 μl of SYBR Green Master Mix, and 1 μl of primers
(5 μM) specific for PTN, ALK, RPTPβ/ζ, MK, or the ribozyme expres-
sion vector (SP6 and T7 primers). To normalize for equal loading, all
samples were run in parallel with actin primers. A preincubation for
15minutes at 95°C was followed by 55 amplification cycles: 10 seconds
at 95°C, 10 seconds at 55°C, and 10 seconds at 72°C. The melting
curve for PCR product analysis was determined by rapid cooling down
from 95 to 65°C and incubating at 65°C for 15 seconds before heat-
ing to 95°C.
PTN ELISA
Conditioned tissue culture medium was assayed for PTN protein
essentially as described previously [3]. Briefly, 100 μl per well of a
mouse anti-PTN monoclonal antibody (4B7), diluted to 1 μg/ml in
Tris-buffered saline (TBS), was incubated in covered 96-well ELISA
plates (Life Technologies, Karlsruhe, Germany) at 4°C overnight. After
washing three times with TBS/0.5% Tween 20 (TBST), wells were
blocked with 200 μl of TBST/1% BSA for 2 hours, washed again,
and loaded with 100 μl of sample per well diluted 1:1 in TBST for
1 hour. After washing, 100 μl per well of biotinylated affinity-purified
goat anti–(human PTN) detection antibody (R&D Systems,Wiesbaden,
Germany) was added at a concentration of 500 ng/ml and was in-
cubated for 1 hour, and wells were washed again and incubated with
100 μl per well of Streptavidin-AP conjugate (Roche Diagnostics,
Mannheim, Germany; 1:5000 in TBST) for 1 hour. After a final
wash, the signal was revealed with 100 μl per well of p-nitrophenyl
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phosphate substrate solution for 2 hours, and absorbance was mea-
sured in an ELISA reader at 405 nm. Recombinant human PTN
(R&D Systems) served as the standard.
In Vitro Proliferation Assays and In Vitro Scratch Assay
Anchorage-dependent proliferation was assessed essentially as de-
scribed previously [34]. Briefly, cells were plated in quadruplicates
into 96 well plates at, dependent on the cell line, 500 to 1000 cells
per well and cultivated in IMDM/10% FCS in a humidified incuba-
tor under standard conditions. Numbers of viable cells were assessed
using a colorimetric assay according to the manufacturer’s protocol
(Cell Proliferation Reagent WST-1; Roche Molecular Biochemicals,
Mannheim, Germany).
To determine anchorage-independent proliferation leading to col-
ony formation, soft agar assays were carried out as described previ-
ously [35]. Briefly, 20,000 cells in 0.8 ml of 0.35% agarose were
layered on top of 1 ml of a solidified 0.6% agar layer in a 35-mm
dish. Growth media with 10% FCS were included in both layers.
Colonies more than 50 μm in diameter were counted, dependent
on the proliferation rate of the cell lines, after 2 to 5 weeks of incu-
bation by at least two independent investigators blinded to the study.
In vitro scratch assays were performed essentially as described pre-
viously [36]. Briefly, cells were plated in wells, and after 4 days,
scratches were created by scraping with a 200-μl pipette tip. Cell
motility was determined microscopically at the time points 0 and
6 hours by photographing the gaps using a bright field microscope
at low magnification and measuring changes in the gap width.
Apoptosis Assay
To test for in vitro apoptosis, the Caspase-Glo 3/7 assay (Promega,
Madison, WI) was performed according to the manufacturer’s proto-
col. Briefly, 4000 cells per well were plated in 96-well plates and were
cultivated for 3.5 days. A total of 100 μl of Caspase-Glo 3/7 substrate,
reconstituted in buffer, was added per well, and luminescence was mea-
sured after 4 hours using a Fluostar Optima reader (BMG Labtec, Jena,
Germany). To normalize for differences in cell densities, a WST-1 assay
was performed in parallel on the same plate, and the results of caspase
activity, determined in five wells, were adjusted to cell numbers of the
different cell lines.
Tumor Growth in Nude Mice
For the determination of in vivo tumor growth, 3 × 106 glioblas-
toma cells in 150 μl of PBS were injected SC into both flanks of
athymic nude mice (FoxN1 nu/nu). When solid tumors became visi-
ble after 6 days, tumor sizes were determined every 2 to 3 days from
the product of the perpendicular diameters of the tumors for a period
of ∼2.5 to 10 weeks, dependent on the cell line as indicated in the
figure. Intracranial experiments were performed as described previ-
ously [32]. Briefly, mice were anesthetized by i.p. injection of keta-
mine and xylazine (100 and 5 mg/kg bodyweight, respectively) and a
burr hole was drilled into the skull 3.5 mm lateral to the bregma. A
total of 5 μl of a U87 cell suspension adjusted to a concentration of
105 cells/μl containing 0.8% methylcellulose were slowly injected for
5 minutes into the caudate/putamen, using a 30-G needle attached
to a 25-μl Hamilton syringe. All animals were killed after 21 days
when some of the mice started to develop symptoms (weight loss).
Brains were embedded in paraffin, and serial 5-μm sections were
stained with hematoxylin/eosin. The maximum cross-sectional areas
of the glioblastoma xenografts were determined by computer-assisted
image analysis using Leica IM50 software (Leica, Hamburg, Ger-
many), and tumor volumes were estimated by the following formula:
volume = (square root of maximal tumor cross-sectional area)3.
Phospho-MAP Kinase Antibody Array Kit
The activity of a panel of mitogen-activated protein kinases
(MAPKs) and other serine/threonine kinases was assessed through
the determination of their relative level of phosphorylation using
the Proteome Profiler Array (R&D Systems) according to the manu-
facturer’s instructions. Briefly, stable double knockout cells and con-
trol cells were seeded at 50% confluency in wells of a six-well plate,
grown for 2 days, and then lysed at 1 × 107 cells/ml in lysis buffer for
30 minutes at 4°C. After centrifuging at 14,000g for 5 minutes, the
protein concentration of the supernatant was determined, and 250 μl
of lysate, equivalent to 120 μg of protein, of each sample was diluted
in 1.25 ml of Array Buffer 1. Arrays were preincubated in 1.5 ml of
Array Buffer 1 for 1 hour before incubating the arrays in the sample
dilution at 4°C overnight, 3 × 10 minutes washing in 20 ml of wash
buffer, incubating in the detection antibody cocktail (1:100 in 1×
Array Buffer 1), washing, and incubating in a Streptavidin-HRP solu-
tion (1:2000). After washing again, signals were developed by in-
cubating in SuperSignal ECL solution (Thermo Fisher Scientific,
Rockford, IL), and chemiluminescence was visualized by film expo-
sure (Hyperfilm ECL; GE Healthcare, Munich, Germany) for various
periods (10 seconds to 20 minutes) to analyze very strong as well as
very weak spots. Signals were scanned and quantitated using ImageJ
(National Institutes of Health, Bethesda, MD).
Data Analysis
For statistical analysis, one-way analysis of variance/Tukey post-
tests and two-way analysis of variance/Bonferroni posttests were used
(*P < .05, **P < .01, ***P < .001).
Results
Expression of PTN, ALK, RPTPβ/ζ, and MK in Glioblastoma
Cell Lines
Various glioblastoma cell lines were assessed by quantitative reverse
transcription–polymerase chain reaction (RT-PCR) and ELISA for
PTN and ALK expression with major differences being observed.
More specifically, ALK expression was strong in G122 and U87 cells
and weak or absent in G55T2 and T98G cells, but by far the highest
ALK mRNA levels were observed in U118 cells (Figure 1A). Inter-
estingly, the opposite was true for PTN expression, which, in U118
cells, was very low on the mRNA level and below the limit of de-
tection on the protein level, respectively. In contrast, strong PTN ex-
pression was observed in G122, T98G, and U87 cells, with mRNA
levels correlating very well with protein levels (Figure 1, B and C ).
On the basis of these data, G122 and U87 cells were selected for
further experiments, which showed the best combination of strong
PTN expression and ALK expression. Midkine (MK) is a protein re-
lated to PTN, which also signals through ALK and is also involved in
tumorigenesis [37,38]. In G122, U87, and U118 cells, quantitative
RT-PCR for MK revealed only weak MK expression, as opposed to
G55T2 and T98G (Figure 1D). Finally, RPTPβ/ζ expression was
rather low (U118, G55T2, U87MG) or almost absent (T98G) in
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glioblastoma cell lines, with the exception of G122, which showed
very high RPTPβ/ζ levels (Figure 1E ).
Establishment and Analysis of Stable PTN and
ALK Knockdown
Expression vectors encoding ribozymes targeting PTN (Rz66,
Rz261) or ALK (Rz1-3, Rz3-2, Rz12-1) were transfected and stably
integrated into G122 and U87 cells. Reverse transcription–PCR using
primers specific for the ribozyme expression vectors showed bands at
the expected size (∼100 bp, with the PTN Rz PCR product as pre-
dicted being slightly higher than the ALK Rz) in the stably transfected
cells but not in the untransfected wild type cells, indicating the stable
integration of the ribozymes (Figure 2A).
The analysis of ALK mRNA levels in G122 cells revealed a mode-
rate yet statistically significant knockdown efficacy between 20%
(Rz1-3) and 40% (Rz12-1) whereas on transfection of the empty
Figure 1. Expression of ALK, PTN, MK, and RPTPβ/ζ in various glioblastoma cell lines. Levels of (A) ALK mRNA, (B) PTN mRNA, (C) PTN
protein in conditioned medium, (D) MK mRNA, (E) RPTPβ/ζ mRNA are shown.
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vector, ALK remained unchanged compared to wild type cells (Fig-
ure 2B). Considerably more pronounced targeting efficacies were ob-
served in U87 cells with 85% to 90% ALK knockdown, with no
significant differences between the three ribozymes (Figure 2C , left).
Stable transfection with the PTN Rz expression vectors had no effect
on ALK expression levels (data not shown) but resulted in the down-
regulation of PTN expression in G122 and in U87 cells with, again,
the effect being less pronounced in G122 compared to that in U87
cells. More specifically, in G122 cells, a 25% (Rz66) to 50% (Rz261)
knockdown was achieved on mRNA level (Figure 3A), whereas U87
cells showed a >70% reduction in PTNmRNA levels, which was again
independent of the ribozyme (Figure 3C , left). PTN ELISA mea-
surements of the conditioned medium also revealed that decreased
mRNA levels were paralleled by reduced secretion of PTN protein
(Figure 3B), indicating that mRNA reduction correlates well with de-
creased PTN protein expression. No changes in PTN levels were ob-
served on stable ALK targeting (data not shown).
Subsequently, double knockdowns were performed in stable ribozyme-
expressing U87 and G122 cells by stably transfecting the second
ribozyme expression vector. Analysis of ALK (Figure 2C ) and PTN
(Figure 3C ) mRNA levels revealed that knockdown efficacies of each
individual ribozyme remained essentially unchanged on the intro-
duction of the second ribozyme (Figures 2C and 3C , right panels;
data not shown).
Enhanced Antiproliferative Effects on Double Knockdown
of PTN and ALK
Stable reduction of ALK or PTN in U87 cells resulted in a signifi-
cantly decreased anchorage-dependent proliferation (Figure 4, A and
B), which was comparable for both gene products. Notably, however,
double knockdown of both PTN and ALK markedly enhanced the
antiproliferative effects (Figure 4C ) with almost an abolishment of cell
proliferation in the case of the most efficient ribozyme combination,
Rz ALK 3-2/PTN 261 (compare Figures 2C and 3C). Likewise, stable
targeting of both PTN and ALK led to increased antiproliferative ef-
fects in G122 cells compared to single knockdown (Figure 4E).
Soft agar assays rely on anchorage-independent cell proliferation and
thus resemble more closely the in vivo situation. The assessment of
colony formation of U87 cells stably transfected with one ribozyme
expression vector revealed decreased proliferation. This was particularly
true for ribozymes ALK 3-2 or PTN 261 (Figure 4D, left and center
panels), which, in combination, had shown to be most efficient in
the reduction of anchorage-dependent growth (compare Figure 4C).
On double knockdown of both PTN and ALK, a markedly reduced
Figure 2. Ribozyme-mediated knockdown of ALK. (A) Expression of ribozymes in stably transfected cells as determined by PCR. Con-
stitutive expression of ALK ribozymes Rz1-3, Rz3-2, or Rz12-1 leads to a moderate reduction of ALK mRNA levels in G122 (B) and to a
profound ALKmRNA knockdown in U87 cells (C). Targeting efficacies remain unchanged on double knockdown of PTN and ALK (C, right
panel). *P < .05, ***P < .001 compared with vector control.
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colony formation was observed in all ribozyme combinations analyzed,
indicating additive antiproliferative effects over the single knockdown.
In agreement with the data on the anchorage-dependent proliferation
on double knockdown, the combination of ribozymes ALK 3-2 and
PTN 261 resulted again in the almost complete abolishment of tumor
cell proliferation (Figure 4D, right panel ).
To further study cellular effects on PTN/ALK double knockdown,
apoptosis and cellular migration were determined in selected cell lines.
Caspases-3 and -7 play key effector roles in apoptosis, and their activ-
ities were measured in a luminescent assay. In stably ALK ribozyme–
or PTN ribozyme–transfected cells, a ∼1.5-fold increase in apoptosis
was observed. More strikingly, however, on double knockdown of
PTN and ALK, an almost three-fold higher caspase-3/7 activity was
determined (Figure 4F). Likewise, differences were observed regarding
cellular migration as determined by an in vitro scratch assay. Whereas
6 hours after scraping a ∼20% reduction in scratch width was deter-
mined in the case of control cells, no cellular migration was observed
in double knockdown cells (Figure 4G ).
Double Knockdown of PTN and ALK Abrogates SC
Tumor Growth
To test the antitumorigenic effects of the parallel targeting of PTN
and ALK more rigorously, an in vivo subcutaneous tumor xenograft
model was used. Poor proliferation of U87 Rz3-2/261 cells, how-
ever, prevented the generation of cell numbers sufficiently high for
in vivo experiments, and so this cell line had to be excluded, and
the double knockdown cell lines U87 Rz66/1-3 and Rz66/12-1 were
selected instead. Also, reduced tumor growth on single targeting of
PTN or ALK had already been reported previously [21,25] and
was thus not included again in this experiment. Wild type or empty
vector–transfected U87 cells rapidly grew tumors, which were accu-
rately measurable after 6 days. For ethical reasons, the experiment
was terminated in these groups after 16 to 20 days owing to the for-
mation of very large tumors. In contrast, tumor growth was markedly
reduced in cells stably transfected with ribozymes PTN 66/ALK 1-3
with an onset of tumor mass expansion only after day 20 and thus,
after the experiment, had already been terminated in the control
groups. Most strikingly, however, double transfection of U87 cells
with ribozymes PTN 66 and ALK 12-1 completely inhibited tumor
growth for more than a 60-day monitoring period (Figure 5).
Activity of Downstream Signal Transduction Pathways
Finally, the double knockdown cell line U87 Rz ALK 12-1/PTN
66, which also showed reduced tumor growth by >50% compared
to untargeted control cells after stereotactical engraftment of the
Figure 3. Ribozyme-mediated knockdown of PTN. Constitutive expression of PTN ribozymes Rz66 or Rz261 leads to the reduction of
PTN mRNA levels in G122 cells (A), which translates into reduced PTN protein levels in the conditioned media (B). Strong PTN mRNA
knockdown is observed in U87 cells (C). Targeting efficacies remain unchanged on double knockdown of PTN and ALK (C, right panel).
*P < .05, **P < .01, ***P < .001 compared with vector control.
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cells into the caudate-putamen of nude mice (Figure 6C ), was further
analyzed about changes in downstream signal transduction pathways.
Using a phospho-specific antibody array, changes in the phos-
phorylation status of important regulators of signal transduction were
analyzed after PTN/ALK double knockdown, including all three
major families of MAPKs, the extracellular signal–regulated kinases
(ERK1/2), c-Jun N-terminal kinases (JNK1-3), the different p38 iso-
forms α, β, δ, and γ, as well as the serine/threonine kinases Akt1, 2,
3, the glycogen synthase kinase GSK-3, and p70 S6 kinase (Fig-
ure 6A). Arrays were incubated in parallel with lysates from the dou-
ble knockdown cell line U87 Rz ALK 12-1/PTN 66 and from
untargeted control cells, and arrays were exposed to films for different
periods not only to avoid film saturation when quantifying strong
signals but also to detect very weak signals (see Figure 6B for one rep-
resentative example). The comparison revealed that, on PTN/ALK
double targeting, phosphorylation of HSP27, ribosomal kinase 2
(RSK2), and Akt3 dropped to levels below the level of detection even
after a very long exposure to film. Essentially, no changes were ob-
served in JNK and ERK phosphorylation, and changes in akt were
limited to Akt3. In contrast, increased phosphorylation on PTN/
ALK double knockdown was observed for RSK1, all members of
the p38 family, GSK-3α, and GSK-3β, as well as for p70 S6 kinase
(Figure 6A). Taken together, this indicates a rather complex pattern of
changes in various signal transduction pathways.
Discussion
The growth factor PTN as well as both receptors involved in PTN
signaling, ALK and RPTPβ/ζ, have been shown individually to be
rate-limiting for glioblastoma growth and thus to play a pivotal role
in this highly malignant tumor [21,25,32]. Owing to the genetic in-
stability of tumor cells, which may lead to autocrine counterregula-
tions and the probably limited efficacy of any targeting strategy,
however, a single knockdown or inhibition may not be sufficient
in a therapeutic setting, and the parallel inhibition of more than
one gene involved in a given signal transduction pathway may be
Figure 4. Antiproliferative effects of ribozyme-mediated knockdown of ALK (A) or PTN (B) in U87 cells. Double knockdown of PTN and
ALK leads to a further reduction in U87 (C) and in G122 cell proliferation (E). Soft agar assays monitoring anchorage-independent cell
growth of U87 cells confirm the enhanced antiproliferative effects on double knockdown (D). Caspase-3/-7 assays indicate increased
apoptosis on single gene targeting of PTN or ALK and, more profoundly, in double knockdown cells (F). A scratch assay also reveals the
inhibition of cell migration on PTN/ALK double knockdown as determined by the fold change in scratch width 6 hours after scraping (G,
left; see right panel for representative examples). *P < .05, **P < .01, ***P < .001 compared with vector control.
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Figure 4. (continued )
Figure 5. Abrogation of SC U87 tumor xenograft growth on PTN/ALK double knockdown using ribozymes PTN Rz66 and ALK Rz12-1.
Right panel: Representative tumor-bearing mice at the time points of termination of the experiment as indicated in the growth curves.
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more efficient especially in long-term therapy. In fact, previous stud-
ies on PTN or ALK single knockdown showed best results only on
the selection of stable cell clones with highest knockdown efficacies
[21,25]. This is barely achievable and thus probably not realistic in
the setting of a therapeutic intervention in vivo. Moreover, the exis-
tence of an alternative ligand for the ALK receptor, MK [38], may
limit the therapeutic efficacy of a single knockdown of PTN. Thus,
this study aimed at the parallel knockdown of both ligand and recep-
tor of the PTN signal transduction pathway.
Selection of Target Molecules for Double Knockdown
Besides PTN, we selected ALK because this receptor tyrosine ki-
nase has been shown to act as a PTN binding molecule and thus as a
direct receptor [24,39] as well as to be a crucial downstream signal
transduction molecule in the RPTPβ/ζ pathway on PTN activation
[31]. Hence, despite one study that failed to show the activation of
ALK by PTN [40], a huge body of evidence indicates that ALK is
crucial in PTN signal transduction. Consequently, the issue whether
both pathways, RPTPβ/ζ–dependent and –independent, exist in par-
allel and are functionally relevant for PTN signaling, is less important
here about the expected increase in therapeutic efficacy on double
knockdown of PTN and ALK. This is also true for the distinction be-
tween the two naturally occurring forms of PTN (15 and 18 kDa)
[39]. PTN 15 and PTN 18 have been described to act differently, with
PTN 15 promoting glioblastoma proliferation in an ALK-dependent
fashion and immobilized PTN 18 promoting haptotactic migration
of glioblastoma cells in an RPTPβ/ζ–dependent fashion [39]. How-
ever, because the PTN isoforms differ by posttranslational processing
of 12 C-terminal amino acids, they are both targeted in our approach.
Indeed, the parallel knockdown of PTN and ALK strongly en-
hanced antitumorigenic effects in glioblastoma growth as shown
here in different cell lines and in different in vitro and in vivo models.
Our expression analysis data, however, also demonstrate striking dif-
ferences between various glioblastoma cell lines regarding PTN,
Figure 6. Antibody array data to assess the activity of downstream signal transduction pathways. (A) Quantitation of phosphorylation
signals in U87 cells with stable PTN/ALK double knockdown, which abolished the growth of SC tumor xenografts (PTN Rz66/ALK Rz12-1,
gray bars), compared with control cells (black bars). (B) Representative examples of various film exposures with (upper panels) a total
overview and (lower panels) selected areas after shorter or longer exposure time. (C) The selected double knockdown cell line shows
markedly reduced tumor growth compared with control cells also in an orthotopic tumor model.
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ALK, MK, and RPTPβ/ζ expression, which is in agreement and fur-
ther extends previous studies [25,39,41]. This is true, for example,
regarding the absence of ALK and RPTPβ/ζ in T98G cells, and
consequently, ribozyme-mediated ALK targeting did not exert any
growth-inhibitory effects in this cell line (data not shown). Because
PTN knockdown, however, still provides antitumorigenic effects in
T98G cells (data not shown), this also indicates that non–ALK-
mediated PTN signal transduction pathways exist as suggested previ-
ously (see, e.g., [40]).
Impact of PTN/ALK Targeting on Signal Transduction
Our phosphorylation assay data also demonstrate the presence of
PTN/ALK–dependent pathways, beyond the ones already described
in the literature, initiating proliferation and tumorigenesis. More specifi-
cally, it was shown previously that PTN activates phosphatidylinositol
3-kinase and MAPK pathways [24,25] and induces the phosphorylation
of ALK and of the downstream effector molecules IRS-1, Shc, phos-
pholipase C-γ, and phosphatidylinositol 3-kinase, thus mediating
growth stimulatory [24] and antiapoptotic effects [23]. Furthermore,
ribozyme-mediated targeting of ALK prevented PTN-stimulated Akt
phosphorylation, leading to antitumorigenic effects [25]. Importantly,
the stable down-regulation used here, as opposed to transient targeting
or stimulation approaches, relies on a somewhat prolonged cultivation
of the cells under knockdown conditions and thus allowed us to study
the cells after adaptation, i.e., after at least partial counterregulation
of growth inhibitory effects, thus mimicking prolonged therapeutic
intervention. Interestingly, the inhibition of the ERK1/2 signaling
pathway, which has been described previously to be relevant in PTN
and ALK [38–40,42–44] signaling, was lost on prolonged double
knockdown of PTN and ALK, as indicated by unchanged degrees of
phosphorylation. This suggests the parallel activation of other prolifera-
tive pathways that signal through ERK1/2. In this context, it should be
noted that Heroult et al. [45] found PTN to associate with VEGF165
through the thrombospondin type I repeat domains, suggesting that
PTN blocks VEGF165 binding to its receptor. Consequently, this ef-
fect would be abrogated on PTN targeting and may account for un-
changed net levels of ERK1/2. In fact, the constitutive activation of
MAPK particularly in U87 glioblastoma cells has also been described
previously [25].
Strikingly, the PTN/ALK double knockdown is sufficient to in-
duce the complete abolishment of tumor growth as in the case of
Rz66/12-1, also indicating that pathways other than ERK1/2 deter-
mine the (loss of ) tumorigenic potential of glioblastoma cells. In-
deed, the phosphorylation array shows significant changes in the
activation of other downstream signal transduction molecules, which
persist also for a prolonged knockdown period. This is true for Akt3
and, to a minor extent, for Akt2, which is in agreement with earlier re-
ports that Akt acts downstream of ALK [38] and is stimulated by PTN
in ALK-expressing but not in ALK-negative cell lines [23,25,39]. Be-
cause the serine/threonine kinases Akt (also called PKB) are known to
be regulators of growth factor–mediated cell signaling involved in vari-
ous biologic processes including cell proliferation and tumorigenesis,
the finding of Akt inactivation on double knockdown fits well to the
observed antitumorigenic phenotype.
Identification of Other Pathways Relevant in
PTN/ALK Signaling
Other pathways that have been less well explored or so far have
not been described at all in the context of PTN/ALK seem to be
involved as well. The antibody array data indicate a marked activa-
tion of GSK3α and GSK3β, which are involved in the regulation of
various cell functions, on double knockdown of PTN and ALK. This
is in line with the above-mentioned finding of decreased Akt activity
on ribozyme transfection, because PKB/Akt, which is frequently ac-
tivated in cancers [46], phosphorylates and inhibits GSK3, with de-
creased Akt activity, consequently leading to GSK3 activation.
Furthermore, certain growth factors including, for example, endothe-
lial growth factor, have been shown to inhibit GSK3 activity (see
[47]), and our results now extend these findings toward PTN/
ALK. The activation of GSK3 on PTN/ALK knockdown is particu-
larly important because GSK3 acts as a potential tumor suppressor
protein in the Wnt signaling pathway, thus leading to decreased ex-
pression of oncogenic proteins (see [48] for review), and the reversal
of the aberrant GSK3 inhibition in glioblastoma cells may well con-
tribute to the reduced tumorigenesis observed in our study.
Likewise, a marked activation of p38 is observed on PTN/ALK
double knockout. Because the p38 MAPK pathway has been de-
scribed as a negative regulator of cell proliferation and tumorigenesis
with persistent activation of the p38 pathway, thus inhibiting tumor
formation, this finding again fits very well to the observed anti-
tumorigenic effects on ribozyme-mediated double targeting of PTN
and ALK.
Mad1 is a substrate of both p90 RSK and p70 S6 kinase, and the
phosphorylation of Mad1 accelerates its ubiquitination and proteasome-
mediated degradation, thereby inhibiting its tumor suppressor function
[49]. Consequently, because the phosphorylation and thus activation of
RSK promotes tumor cell proliferation, the absence of activated RSK2
on PTN/ALK double knockdown again corresponds to the finding of
decreased proliferation. In contrast, however, the activation rather than
inactivation of P70S6 and RSK1 kinases may at least partially counter-
act this effect by restoring Mad1 degradation and stimulation of cell
proliferation under double targeting conditions. This indicates an ob-
viously more complex interplay between both pathways acting on
Mad1 and thus on tumor cell proliferation, which will require further
analysis also in the context of PTN/ALK double knockdown.
Finally, the double knockdown of PTN/ALK led to the inactiva-
tion of Hsp27. Heat shock proteins including Hsp27, which are in-
duced in cells exposed to stress and which function as molecular
chaperons in protein folding, have been implicated in cancer [50],
and Hsp27 is involved in cell growth. Consistent with that, Hsp27
expression has been shown to correlate with the degree of malignancy
of glial tumors with very high levels in glioblastomas (WHO grade IV)
as well as in U87 cells [51]. Again, the reduction of activated Hsp27
below the level of detection on ALK/PTN double knockdown may
add to the antiproliferative effects of the ribozymes.
Thus, beyond the already established signal transduction pathways
for PTN and ALK, we identify other relevant pathways, indicating a
more complex pattern of PTN-mediated signaling through ALK.
Therapeutic Relevance of Double Inhibition Strategies
In recent years, gene targeting approaches have gained increased
attention owing to the discovery and exploration of RNAi in vitro
and particularly in vivo (see, e.g., [52] for review), with siRNA prob-
ably providing even more powerful tools than ribozymes especially
for the transient therapeutic knockdown. As shown in this study,
the establishment of double targeting strategies, which go beyond
the knockdown of a single gene product such as PTN [22] and
may also include alternative strategies including inhibitory antibodies
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for ALK [40], will likely enhance therapeutic efficacies. This may
be because the inhibition of PTN or ALK is less than 100%, which
would probably also be true in any therapeutic setting and suggests
that additive effects are observed on double knockdown. Further-
more, it has been shown in other systems that the independent in-
hibition of a given pathway at two steps can exert synergistic effects,
e.g., by helping to avoid autocrine counterregulation events or the
formation of resistance. This may be true here particularly in the light
of the complexity of the pathway(s) about the existence of two ligands
and two receptors. Thus, double knockdown strategies may offer novel
approaches for therapeutic interventions, particularly in malignancies
with poor prognosis as, for example, in glioblastoma.
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